Executive Leadership

Dr. Nakamura is our Chairman and CEO. He started a first CRO in Japan in 1992 and greatly contributed to found the Japan CRO Association with three other companies working in the field at that time Dr. Nakamura served as secretariat for 5 years from its establishment. As a chairman of the Japan CRO Association from 1999 until 2002, Dr. Nakamura dedicated his time and broad network in this industry to expand the Association and the CRO industry in Japan as a whole. The history of CMIC directly reflects the history of CROs in Japan. Prior to founding CMIC, Dr. Nakamura was a project team leader of the development of Pravastatin, a blockbuster drug primarily used for the treatment of dyslipidemia and the prevention of cardiovascular disease, in Sankyo Co., Ltd.

Dr. Nakamuara earned his bachelor’s degree from Faculty of Pharmaceutical Sciences, Kyoto University and doctoral degree from Graduate School of Natural Science & Technology, Kanazawa University.

Dr. Nakamura said, “CMIC Group pioneered the CRO business in Japan. We started out to support the development of pharmaceuticals, and it now offers greatly expanded services that encompass an entire value-chain of pharmaceutical companies, including manufacturing, sales, and marketing, based on our unique “Pharmaceutical Value Creator (PVC)” business model.　We also offer services to medical device manufacturers, academia, bio-ventures, and medical institutions. We also provide prophylaxis and health enhancing services to the public. We will continue to establish business models that create further value and contribute to greater advances in the pharmaceutical industry.”

Ms. Oishi is the President and COO of CMIC HOLDINGS Co., Ltd., responsible for group-wide business execution.

Ms. Oishi received her Master of Science degree from the University of Tokyo. She started her career at Nikkei McGraw-Hill, Inc. in Japan (now renamed Nikkei Business Publications), as a staff writer for Nikkei Biotech, the first Japanese newsletter specializing in biotechnology. She accumulated her biotechnology industry career through working in Genzyme Japan, Ltd., and Genentech, Ltd., a Japanese Branch of Genentech, Inc. in the U.S.

Ms. Oishi joined CMIC in 1996, as Manager of the Strategy Development Department. Over the past 20 years, she has been responsible for International Business and Corporate Development, covering Japan, Korea, China, Singapore, Taiwan and other regions in Asia Pacific, as well as for International Business Development which function could bring in foreign pharma and biotech companies that are interested in drug development in Japan and Asia, to start their regulatory and clinical activities in the region. With her broad international experience and strong leadership, she continuously leads the company to further globalization.

Mr. Mochizuki joined CMIC in 2005 as an executive officer for internal control and corporate finance and was assigned as Chief Financial Officer in 2012. Since then, he has been responsible for directing the fiscal functions of the corporation in accordance with generally accepted accounting principles and other regulatory and advisory organizations and in accordance with financial management techniques and practices appropriate within the industry. Prior to CMIC, Mr. Mochizuki served as a corporate officer for finance at the US-based venture company of the networking device and led the company to achieve the IPO on the Second Section of the Tokyo Stock Exchange. Served as various senior roles in finance, Mr. Mochizuki contributed to develop corporate strategy and establish cross-functional partnerships in the financial point of view. Mr. Mochizuki started his career outside the healthcare industry until he joined Site Support Institute Co., Ltd., Site Management Organization of CMIC Group; however, as pharmaceutical companies and other healthcare industries faced revolutionary changes, he would play a part of the leadership roles in CMIC Group bringing innovation in this industry by providing new services and products.

Mr. Mochizuki received a bachelor of arts in Commerce from WASEDA University.

Mr. Katayama started his career as an analyst for the pharmaceutical sector at Nomura Securities and he has more than 25 years of leadership in the industry. Before joining CMIC, he served as Chief Executive Officer at Stockport Advisors. He also held several leadership positions with Deutsche Bank AG, Tokyo Branch from June 2014 through June 2017. He was co-head of investment banking coverage at Lehman Brothers Japan and then worked in the investment banking department at Nomura following its acquisition of the failed Wall Street bank in 2008. He spent eight years as a senior banker at Goldman Sachs in Japan. He has advised many top Japanese firms in the chemicals, healthcare, pharmaceutical, consumer, retail, and entertainment industries during his career.

Mr. Katayama received his bachelor’s degree from International Christian University and an MBA from Alliance Manchester Business School.

Mr. Matsukawa joined CMIC in 2012 as an executive officer for Corporate Planning and IPD business. Since 2013, he has been responsible for Corporate Business Development. Mr. Matsukawa started the first 15 years of his career at pharmaceutical and medical device companies, such as Baxter Healthcare. He made his career move to join Starbucks Coffee Japan as head of HR to build business foundation and also served as the head of marketing. Mr. Matsukawa became head of HR and corporate planning at Pacific Golf Management owned by Lone Star, where he turned around bankrupt golf course companies to achieve IPO listing at Tokyo Stock Exchange. Prior to joining CMIC, Mr. Matsukawa served as the head of HR/VP at Quintiles Japan. Currently, Mr. Matsukawa is the Representative Director & CEO of CMIC CMO Co. Ltd. (CDMO business) , as well as a board member, Corporate Director, Vice President (Head of Corporate Development)

Mr. Mitake has been the President of CMIC Co., Ltd. since 2022. Mr. Mitake joined CMIC Clinical Operations in 1993. He was an early member of the team that established CMIC’s CRO business in Japan until 2004. From 2004 to 2007, Mr. Mitake served as the President of GreenPeptide Co., Ltd. (now BrightPath Biotherapeutics Co., Ltd.), which is a venture company that was started out of Kurume University. GreenPeptide performs research and development, manufacturing, and marketing for onco-immunotherapy drugs. He spearheaded the first-in-human clinical trials for cancer peptide vaccines on patients with hormone-refractory prostate cancer and glioblastoma in Japan. He raised 3 billion Japanese yen of venture capital to fund these phase 2 trials. After returning to CMIC in 2007, Mr. Mitake held several senior management roles including branch office manager, executive director of CMIC Korea, corporate officer for business development, President of CMIC PMS, the CMIC BIORESEARCH CENTER, and the President of CMIC HealthCare Institute, Ltd. His innovative work has helped CMIC obtain a patent on CRO industry report documentation systems. Prior to joining CMIC in 1993, Mr. Mitake was a project leader for several drugs in clinical operations in TAIHO Pharmaceutical Co., Ltd. His mother was diagnosed with an unknown eye disorder when he was in elementary school. This was instrumental in Mr. Mitake’s decision to pursue a career in the healthcare field. He has strived to develop innovative drugs, preventive medicine, and personalized medicine. Mr. Mitake received a bachelor’s degree in Pharmacy from Toho University. Pharmacist.

Mr. Okuda is co-head and COO of Clinical CRO Business Unit of CMIC Group.
Additionally, he has been appointed as a board director of CMIC Co. Ltd (since 2017) and CMIC Pharma Science (since 2021). He was the President & Representative Director of CMIC ShiftZero K.K., a joint venture between CMIC Holdings and ShiftZero K.K. (2016-2023). Prior to joining CMIC group business, he was involved in pharmaceutical development as a clinical team member and project manager at Roche (now Chugai) and RPR (now Sanofi) for 15 years in total. After that, he started to work with UK-based consulting/project management company (Fulcrum Pharma development Ltd) to establish Japanese branch and subsidiary company with oncology specific CRO named Niphix K.K. from 2000-2014.
His areas of expertise include strategic pharmaceutical development planning/consulting, oncology drug development, project management, and corporate management. He received a master’s degree in pharmaceutical science, organic chemistry for Tokyo University of Science, Tokyo Japan.

Eri Sekine
Executive Vice President of CMIC Co., Ltd.,

Ms. Eri Sekine joined CMIC CO., Ltd. in 2023 as the Executive Vice President. She currently oversees the Global Data Business functions in One CMIC CRO Business, which encompasses Clinical Data Management, Biostatistics, Statistical Analysis, Pharmacovigilance, Outsourcing Control, and Quality Management. Addition to that, she leads the DX strategy development and implementation in One CMIC CRO. With over 35 years of experience in clinical development, she has specialized in Data Science and Clinical Operations. Prior to joining CMIC, she held positions related to Clinical Operations and Data Science at Novartis Pharma in Japan, including Region Head Trial Monitoring Japan and Japan Head of Oncology
Biometrics and Data Management. Before that, she worked at Wyeth Research, Quintiles, and Syntex. She remains actively involved in industry activities, having previously served as the Japan Country Lead for TransCelerate, and currently holds memberships in the Advisory Council Japan and several Communities at DIA.

Mr. Takashi Asahi is Vice President of CMIC Co. ltd. and started his career as a researcher in a pharmaceutical company after graduating with Master’s degree in Pharmacy. He has more than 25 years of drug development experience in both pharmaceutical and CRO business. He joined CMIC in 2014 as Director of the Clinical Development department. Later, he went on to lead the clinical development such as project management, clinical operations and
consulting at CMIC. His core expertise and strengths are in strategic development planning, clinical operations, project management, and interactions with regulatory agencies and key opinion leaders. He is responsible for overseeing project management and clinical operations in Japan and the APAC region from April 2024, and collaborates with international companies on the adaptation of their products for the Japanese market.

Mr. Yoshida joined JCL Bioassay Co., Ltd. (currently CMIC Pharma Science Co., Ltd.), a company engaged in the bioanalysis business, as the head of the administration department in 2009. In 2012, he was appointed as a director of the company, where he was responsible for strategic planning, investor relations, finance and accounting, and human resources.

In 2015, through a stock exchange with CMIC HOLDINGS Co., Ltd., he joined the CMIC Group. From 2016 to 2022, he served as the Finance and Accounting Department Manager for CMIC HOLDINGS Co., Ltd., overseeing the finance and accounting responsibilities of the CMIC Group. In October 2022, he was appointed as the Executive Vice President and CFO of CMIC CO., Ltd., overseeing the Corporate Department (Finance and Accounting, Human Resources, IT, and Legal). Since April 2024, he has been overseeing the finance and accounting of the entire APAC region for the Clinical CRO business.

Mr. Kosaku is the Co-CEO of CMIC Pharma Science Co., Ltd. CMIC Pharma Science Co., Ltd.. is a non-clinical CRO that is part of CMIC Group. Mr. Kosaku’s mandate is to lead the company in highly competitive non-clinical areas and to provide comprehensive product lifecycle solutions. Mr. Kosaku has been with CMIC since 2004, holding various senior management positions in the CRO business in areas including business development, clinical operations, and corporate planning. Prior to joining CMIC, he was a clinical operations and clinical planning project leader at Japan Tobacco, Inc. At Japan Tobacco, he was engaged in global clinical projects at RWJPRI (currently Janssen Pharmaceutical) and he was a Director of regulatory affairs leading marketing approvals for 2 anti-HIV drugs. Mr. Kosaku received his master’s degree in Agricultural Chemistry from the University of Tokyo.

Takahiro Natsume, Ph.D.
Division Director of Non-Clinical Research

Dr. Natsume is the CEO of Hamamatsu Pharma Research, Inc. Hamamatsu Pharma Research is a non-clinical CRO that is part of CMIC Group. He joined Hamamatsu Pharma Research in October 2016. Dr. Natsume has extensive experience in pharmacological testing and medical imaging with non-human primates. Before joining Hamamatsu Pharma Research, he served as Associate Professor at Fujita Health University and contributed to the research for medical image analysis in clinical studies. Prior to that, he belonged to the Seirei Hamamatsu and Seirei Mikatahara General Hospital, Department of Radiology. He graduated from Faculty of Health Sciences, Fujita Health University in 2001 and received his Ph.D. degree from Graduate School of Medicine, University of Mie in 2007.

Mr. Kawaratani has been engaged in global business development / alliance managements and market access as a global leadership team member in UCB and Sankyo Co. Ltd. for more than 20 years. He started his career in the pharmaceutical industry more than 35 years ago as a clinical development member followed by being PM in Europe to clinically evaluate more than 1.5 dozen projects in their clinical POC. He joined CMIC in 2017 to head strategic regulatory division which now has top share in the industry in Japan. Currently he is co-heading Consulting and Navigation Unit in CMIC Holdings together with Dr. Yoshimasa Shimoto as partners to guide Japan country senior managers / executives in pharmaceutical industries / bio-ventures in Japan leveraging their wide and strong career in the industry. With their team, CMIC provides best planning strategically with operational regulatory supports to jumping into Japanese market for bio-ventures newly coming/expanding into Japan, leveraging CMIC’s pharmaceutical value chain functions with their subsidiaries covering non-clinical/clinical development, CMC/manufacturing, QM,/QA PV, MA and Sales/Marketing operations.

Mr. Matsubara is in the CEO Office and is Risk/Crisis Management Responsible Personnel. Previously, Mr. Matsubara held roles including President of Healthclick and Unit Head of CMIC Healthcare. He has also held General Director of CMIC Vietnam, senior director roles in New Business Development, Finance/Accounting, Corporate General Administration and internal audit. Prior to joining CMIC in 2008, Mr. Matsubara was Director of Learning and Development at Quintiles Transnational Japan starting in 2006. Before joining Quintiles Transnational Japan, he worked at the President’s Office of Sankyo Co., Ltd., where he managed merger and divestiture negotiations. Mr. Matsubara graduated from Shizuoka College of Pharmacy with a bachelor’s degree in pharmacokinetics. He has more than 20 years of healthcare industry experience that he can utilize to help expand business in the Vietnamese and neighboring country markets. Pharmacist.

Mr. Sakazaki is the Head of Site Support Solutions and also serves as Vice President and Director of CMIC Healthcare Institute Co., Ltd. Since joining the CMIC Group in 2004 as an SMA (Site Management Associate) in SMO (Site Management Organization), he has gained extensive experience in various roles and positions, including CDMO (Contract Development Manufacturing Organization), healthcare business, and CMIC Holdings, allowing him to have a broad understanding of the industry’s operations. He leverages this experience to drive business development and oversee organizational operations. Additionally, prior to joining CMIC Group, Mr. Sakazaki has experience in a completely different industry, and his ability to think with a unique perspective and approach things from multiple angles is a strength that enables him to plan business strategies effectively. He has a
unique educational background as well, having graduated from NSSU (Nippon Sport Science University) with a specialization in sports science. Moreover, he holds a national qualification as a career consultant in human resources.

Ms. Kasai is the Division Director of CMIC Career Business. Until 2020, she served as the President of CMIC Career Co., Ltd.

She is responsible for the HR services that CMIC provides, including recruiting services, provision of temporary personnel, and contract services in the healthcare industry. Ms. Kasai joined CMIC BS Co., Ltd. in 2007 as a site manager from the pharmacovigilance department of a foreign-affiliated pharmaceutical company. Prior to joining CMIC, Ms. Kasai worked in several different industries and held various roles, including elementary school teacher, sales manager and art director at a company publicly listed on JASDAQ, and director of a resort hotel. Since becoming affiliated with CMIC, she has contributed to society through her support of healthcare workers. Looking ahead, one of Ms. Kasai’s goals is to develop new models for nursing care facility management in order to help serve an aging society. Ms. Kasai received her Bachelor of Education in Child Psychology, with teaching licenses for Elementary School (Type 1), Junior High School (Type 1), and High School (Type 2). She is also a certified Executive Coach and Executive Career Consultant.

In 1997, Mr. Takayuki Nakamura planned and developed Japan’s first Saas service in the EC
(electronic commerce) field at Nippon Telegraph and Telephone Corporation. After that, he
used his technical experience to support the new businesses of multiple venture companies,
including Q&A/FAQ services and electronic abstracts.

In 2016, Mr. Nakamura founded OKEIOS Co., Ltd. The company planned and developed
an information distribution platform with authenticity, confidentiality, and traceability using
the blockchain technology and started a data utilization business in the health and medical
sectors. Currently, he is leading the CMIC Trust Co., Ltd. and developing individual-driven
information utilization services centered on the PDS/information bank/data trading market.

Masami Terashima
CEO of animo Co., Ltd.

Mr. Terashima started his career as a security guard at SECOM and spent 20 years in IT operations to develop e-Japan system under Obuchi cabinet, Identrus system for SANWA Bank (now, Mitsubishi UFJ Bank) in 2000 and joint venture subsidiary with NTT and Price Water house. Before joining CMIC, he served as Managing Director at Genesis Healthcare Co. to develop B2B business customers to let their employees to use self-genetic testing by using saliva and secretary general of Medical Clinic SOSEIKAI to consult one of major pharmaceutical companies to develop new pharmacy for MC (multiple sclerosis) with
IVD genetic testing. He also spent more than 10 years in some subsidiaries of Mitsui group, Mitsui Knowledge Industry as account manager of SONY and Aramark Uniform Service to re-generate internal system with Dutch ERP system. He spent several years in Healthcare division of Mitsui & Co., Ltd to invest to one of major genetic testing company, Genesis Healthcare Co. Mr. Terashima received his bachelor’s degree in Safety Engineering from Yokohama National University and an MBA from Denver University.

Kazutaka Echigo

CFO(Chief Financial Officer), In charge of Internal Control

Mr Echigo is CPA (Certified Public Accountant) in Japan. After graduating Tokyo
University, he started his career as an accounting auditor at Deloitte Touche Tohmatsu LLC from 2001, and registered CPA in April 2004. He had engaged in several financial engagements until 2019, such as financial Instruments and Exchange Law audit for listed company, IPO services, M&A transaction advisory service, IFRS consulting services. He had seconded to Deloitte Vietnam Hanoi office from 2012 to 2016 as Japanese Service Group, and performed several global transactions, and organized several tax seminars in Vietnam. He had also worked as sub-leader Tax committee of The Japan Chamber of Commerce and Industry in Vietnam. He joined CMIC Group in August 2019, and had engaged mainly in CMIC CMO Co., Ltd. He was appointed as CFO in CMIC CMO from June 2021 to September 2024. He supervised management and financial accounting, mid-term management plan and budget.

Mr. Fukushi is the Chief Creative Officer of CMIC HOLDINGS Co., Ltd. and the Vice Chairman of harmo Co., Ltd. From 2019 to 2021, Mr. Fukushi served as the Director of CMIC TechLab, laying the foundation for the creation of new technologies from CMIC Group.

All of the PHR services currently offered by CMIC Group, including “harmo Okusuri-techo”, “harmo Vaccine Care”, and “harmo Vaccine Care with COVID-19”, were created by him and his valuable patent portfolio has dramatically increased the competitiveness of these services.

Prior to joining the CMIC Group, he worked for Sony Corporation from 2000, where he conducted basic research on image and sound improvement. His own health problems led him to become an in-house entrepreneur, launching Sony’s first new business in the healthcare field, “harmo Okusuri-techo”.

Mr. Fukushi earned a Bachelor of Science from Tokyo University in March 1998 and Master of Science in March 2000.

Hidetoshi Takeda is Senior Advisor, representing CMIC’s U.S. business as well as the strategy and planning unit.  Prior to joining CMIC in 2016, Mr. Takeda was a VP, Portfolio Manager at Permal Group in New York, where he was responsible for managing the firm’s Japan-focused alternative fund products since 2007.  Previously, he was an Assurance Associate at Pricewaterhouse Coopers in Chicago in the firm’s audit service group during 2005 and 2007.  Mr. Takeda began his professional career at Resona Trust & Banking Co., Ltd in Japan as a Fund Manager in the firm’s Trust Fund Management Division in Japan in 2001.  He earned a Master of Accountancy degree from the Kelly School of Business at Indiana University in 2005 and a Bachelor of Arts degree in economics from Kyoto University in 2001.  He is a Chartered Member of The Securities Analysts Association of Japan and is a former Certified Public Accountant in the state of Illinois.

Nakoto Sakurai
CHRO (Chief Human Resources Officer)

Nakoto Sakurai graduated from Hitotsubashi University, majoring in Organizational Development, Change Management, Cultural Shift, and Transformational Leadership. After graduation, she joined RECRUIT Holdings in the HR Business Unit, where she worked for 12 years. She began her career as an HR Consulting Sales professional, working with clients across multiple industries of various sizes and stages. She provided consulting services and developed talent strategies aligned with each client’s growth objectives. Her client portfolio included a total of 500 organizations. Additionally, she played a key role in internal talent development within the HR business and was involved in strategic planning for HR product offerings. After leaving RECRUIT, she co-founded her own company and spent 5 years focusing on organizational transformation by designing and observing “Being.” She also supported international companies entering the Japanese market, providing guidance and leadership in building their organizations from scratch to scale. For 6 years, she served as the Japan HR Talent Acquisition Head at Abbott, a US Medical Device Company. Under her leadership, the Japan team achieved various APAC and Global awards for D&I initiatives, branding, international talent recruitment and development, and talent market analysis. In 2023, she obtained a certificate in Fundamental Business Leadership from IMD Business School in Switzerland. In 2023, she joined CMIC Holdings as the Director of the Strategic Group HR, and in 2024, she was appointed as the CHRO (Chief Human Resources Officer) to lead the Group HR strategy.

Mr. Saito joined CMIC in 2019 and has led the Legal and Compliance team at CMIC Group, supporting the company from both perspectives of guardian and business partner. He is an attorney admitted in Japan and the State of New York, USA. Mr. Saito started private practice as a lawyer in 1992 and has worked at multiple large US and Japanese law firms including a career in the USA from 1997 to 2002. After working at CITY YUWA Partners as a partner, Mr. Saito joined GE as an in-house counsel in 2007 and then worked at Shinsei bank as a manager of legal division, AIG Japan as a general counsel until 2018. Besides legal practice, Mr. Saito serves as a mediator at Tokyo Bar Association, Trust Association, Nuclear Damage Compensation Dispute Resolution Center and as a member of Financial ADR committee at Financial Services Agency (FSA). Mr. Saito has been teaching business law at Meiji University Law School and Business School, and also financial law at Tsukuba University Law School since 2013.

Mr. Sano is the Academy Head of CMIC HOLDINGS Co., Ltd.

Prior to joining CMIC, Mr. Sano served as Executive Vice President and Director at SAGAN DREAMS CO., LTD, an operating company of a professional football team.

Mr. Sano joined CMIC in 2008 as a President of CMIC-MPSS Co. Ltd., currently a joint venture company of CMIC Ashfield Co., Ltd., that focuses on Contract Sales Organization (CSO) business within CMIC Group. Since 2013, he has held various senior management positions, such as Head of Secretarial Office, Human Capital Development Center Director and Liaison Officer.

Mr. Sano has his bachelor’s degree of Faculty of Engineering from Kyoto University.

Dr. Shimoto is the Chairman of Orphanpacific Inc. and the Division Director of Market Solution business unit of CMIC HOLDINGS. He joined the company in June 2021. Prior to joining CMIC, Dr. Shimoto served as Executive Vice President, Clinical Development at Daiichi Sankyo RD Novare Co., Ltd., and was responsible for oversight of clinical studies/clinical researches execution and corporate management. He also had served as Vice President of Global Project Management and Asia Development at Daiichi Sankyo Co., Ltd., and was responsible for portfolio/project management of R&D and clinical study implementation in Asian region, respectively. He provided scientific/regulatory input to the development of an antisense oligonucleotide for duchenne muscular dystrophy, as External Director of Orphan Disease Treatment Institute. He studied abroad at the University of Tokyo in 1988-1989, and at University of Michigan in 1992-1993 as a researcher. He also worked in US as a project manager at Daiichi Pharmaceutical Inc. in 1999-2005.

Dr. Shimoto received a master’s degree in Pharmacy from Chiba University and a doctoral degree from the University of Tokyo.

Mr. Kuwajima joined CMIC in 2019 and is currently the Corporate Director and Vice Chairman of CMIC HOLDINGS Co., Ltd, responsible for strategic management of CMIC Group.

He is also the Chairman of CMIC HealthCare Institute Co., Ltd., which is one of the subsidiaries of CMIC Group which focuses on site and patient activities such as Site Management Organization (SMO) and other healthcare related services. Additionally, he is the Representative Director and Chairman of CMIC Career Co., Ltd., which offers human resource services focusing on the pharmaceutical industry.

In 1997, he was Representative Director of IBRD JAPAN Co., Ltd., which is a CRO company established in 1992. He also served on the board of the Japan CRO Association. In 2006, Mr. Kuwajima established and became the president of Medi-Skette Corporation, a company that provides support for collecting data from clinical trials, post-marketing surveillance and other pharmaceutical studies. Prior to joining CMIC, he served as an Executive Officer at MEDICEO CORPORATION, where he was in charge of Academia Support, Sales Division.

With his broad experience and strong leadership, he brings new ideas and actively takes the lead in creating innovative healthcare services in CMIC Group.

Mr. Kuwajima has a bachelor’s degree in Pharmacy from Toho University. Pharmacist.

Mr. Kuwajima joined CMIC in 2019 and is currently the Corporate Director and Vice Chairman of CMIC HOLDINGS Co., Ltd, responsible for strategic management of CMIC Group.

He is also the Chairman of CMIC HealthCare Institute Co., Ltd., which is one of the subsidiaries of CMIC Group which focuses on site and patient activities such as Site Management Organization (SMO) and other healthcare related services. Additionally, he is the Representative Director and Chairman of CMIC Career Co., Ltd., which offers human resource services focusing on the pharmaceutical industry.

In 1997, he was Representative Director of IBRD JAPAN Co., Ltd., which is a CRO company established in 1992. He also served on the board of the Japan CRO Association. In 2006, Mr. Kuwajima established and became the president of Medi-Skette Corporation, a company that provides support for collecting data from clinical trials, post-marketing surveillance and other pharmaceutical studies. Prior to joining CMIC, he served as an Executive Officer at MEDICEO CORPORATION, where he was in charge of Academia Support, Sales Division.

With his broad experience and strong leadership, he brings new ideas and actively takes the lead in creating innovative healthcare services in CMIC Group.

Mr. Kuwajima has a bachelor’s degree in Pharmacy from Toho University. Pharmacist.

Mike is the President & CEO of CMIC, INC., located in Hoffman Estates, Illinois (near Chicago O’Hare Airport), an emerging lab CRO and a service provider specialized in BioAnalysis for supporting pre-clinical TK and clinical PK/PD biomarker studies during development of biologics and oligonucleotides as well as small molecule pharmaceuticals. The company started lab operation at its purpose-built GLP facility as JCL Bioassay USA in 2010, and joined CMIC Group through acquisition in 2015. Since then, Mike has been in this Chicago-based leadership position, and also led strategic facility investment in 2017, along with CMIC’s new U.S. client base expansion after acquisition and integration.
Prior to joining CMIC, Mike was the Deputy General Manager of GE Healthcare’s CT/MRI contrast media in-vivo diagnostics and PET/SPECT radio-pharmaceuticals division in Japan, where he was the first employee soon after GE’s acquisition of former Amersham, and was responsible for establishing a new pharmaceutical operation reporting into GE Healthcare’s U.K. Headquarters. While at GE, Mike was not only leading a number of pharmaceutical and IP licensing (e.g., Daiichi Sankyo, Sumitomo Chemical, Fujifilm) and regulatory authority (PMDA/MHLW) negotiations, but also was heavily involved in clinical trials (GCP) and CMC development (GMP) both globally (Phase III ~ Post-approval) and regionally(Asian-Caucasian bridging Phase I~II).
Mike started his 30-year professional career as a tissue culture and genomics scientist at JT (now a.k.a. Akros) genetic engineering lab, and later spent five years in New York and San Francisco as JT’s recombinant DNA business development manager. Mike earned bachelor’s and master’s degrees in agricultural biosciences from University of Tokyo. He also completed GE’s internal executive training program at its Crotonville, New York main campus.

Mr. Keino is the President of CMIC Healthcare Co., Ltd. and Senior Vice President of CMIC HOLDINGS Co., Ltd. He joined the CMIC CRO business development group in 1999. Since joining CMIC, he has held leadership roles related to the SMO business startup (in 2001), the CRO business startup in China (in 2005), the SMO business turnaround (in 2007), and the management of the Asian business (in 2010). Since 2015, he has managed CMIC’s Healthcare business. As President of CMIC Healthcare Co., Ltd., Mr. Keino’s mission is to facilitate healthcare innovation by providing comprehensive service solutions in the areas of patient record keeping and patient information sharing. Prior to joining CMIC, Mr. Keino worked at the administrative scrivener’s office supporting documentation and submission of certifications and registrations for medical devices. Mr. Keino received a bachelor’s degree in French Literature from Meiji Gakuin University.

Mr. Lee has been a Representative Director and President of CMIC CMO Korea since 2014. He is responsible for manufacturing supervision (Ointment/Cream/Gel) and quality assurance/control. He joined CMIC CMO Korea as a plant manager and director of production in 2008. He has extensive experience in GMP manufacturing and quality assurance/control in the pharmaceutical industry. Prior to joining CMIC CMO Korea, Mr. Lee served as senior leader and senior manager for quality assurance/control of Korea Otsuka Pharmaceuticals Co., Ltd. and was responsible for managing application and approval work of Asian and Arab registrations. In this capacity, he supervised manufacturing, evaluated operations, and oversaw facilities and equipment capital investments. Mr. Lee started his career in quality assurance/control at SAMIL Pharmaceutical Co. in 1992, helping the company obtain certifications of domestic and foreign GMP. Subsequently, he managed the NDA registration process for drug exportation and GMP inspection of affiliate companies Korea Otsuka Pharmaceuticals and CHOONGWAE Pharmaceuticals. Mr. Lee earned a bachelor’s degree in Pharmacy from Sungkyunkwan University and completed doctoral degree coursework in Pharmacy at Sungkyunkwan University. Pharmacist.

April 1968 Joined The Sanwa Bank, Ltd. (currently, The Bank of Tokyo-Mitsubishi UFJ, Ltd.)
June 1994 Director of The Sanwa Bank, Ltd.
May 1997 Managing Director of The Sanwa Bank, Ltd.
June 1999 President of Sanwa Capital Finance Ltd. (Mitsubishi UFJ Capital Co., Ltd.)
June 2005 The Chairman and Director of Ask Planning Center, Inc.
July 2005 The Chairman of CREEK & RIVER Co., Ltd.
March 2011 The President of Medical Principle Co., Ltd. (to present)
December 2014 External Corporate Director of CMIC HOLDINGS Co., Ltd. (to present)
June 2017 Chairman and Director, ASK HOLDINGS, INC. (to present)
June 2017 Chairman and Director, Wealth Management, Inc. (to present)

Status of Important Concurrent Posts
-The President of Medical Principle Co., Ltd.
-The Chairman and Director of ASK HOLDINGS, INC.
-The Chairman and Director of Wealth Management, Inc.

December 1973 The University of Tokyo
April 1983 Department of Surgery II, Faculty of Medicine, University of Yamanashi
April 1993 Joined Hoechst Japan Co., Ltd., as a head of Medical Affairs Office
January 2005 Joined GlaxoSmithKline K.K.
September 2011 Professor of Departmen Faculty of Medicine, University of Yamanashi
September 2014 Professor of Department of Advanced Biomedical Research in Faculty of Medicine, University of Yamanashi (to present)
April 2015 Vice President of University of Yamanashi (to present)
December 2016 External Corporate Director of CMIC HOLDINGS Co., Ltd. (to present)
Status of Important Concurrent Posts
－Program Officer, Japan Agency for Medical Research and Development
－Visiting Professor, Juntendo University School of Medicine
－Visiting Professor, Ehime University School of Medicine

April 1980 Joined Ministry of Health and Welfare (currently Ministry of Health, Labour and Welfare) July 2000 Director, Public Relations Office, General Coordination Division, Minister’s Secretariat, Ministry of Health and Welfare
July 2004 Director, National Health Insurance Division and Director, General Affairs Division, Health Insurance Bureau, Ministry of Health, Labour and Welfare
July 2009 Deputy Director-General (in charge of Medical Insurance, Health Policy, Health Care and Long-term Care Integration), Ministry of Health, Labour and Welfare
Sept. 2012 Director-General for Policy Planning and Evaluation (in charge of Social Security), Ministry of Health, Labour and Welfare
July 2014 Director General, Health Insurance Bureau, Ministry of Health, Labour and Welfare
June 2016 Director-General for Regional Revitalization, Headquarters for Overcoming Population Decline and Vitalizing Local Economy in Japan, Cabinet Secretariat
August 2016 Retired from Cabinet Secretariat
Status of Important Concurrent Posts
－Visiting Professor, Saku University
December 2018 External Corporate Director of CMIC HOLDINGS Co., Ltd. (to present)

October 1981 Joined Nomura Research Institute, Ltd.
September 1985 Management Consultant, McKinsey & Company
October 1986 Fund Manager, Mercury Asset Management plc, SG Warburg
November 1995 Chief Investment Officer (CIO), Yamaichi Regent ABC Polska
July 1998 Joined Bank for International Settlements
October 2004 Senior Pension Fund Administrator, Organisation for Economic Co-operation and Development (OECD)
March 2008 Representative, Kawai Global Intelligence
April 2012 Professor, Institute for the Promotion of Excellence in Higher Education, Kyoto University
April 2013 Professor, Institute for Liberal Arts and Sciences, Kyoto University
April 2014 Professor, Graduate School of Advanced Integrated Studies in Human Survivability, Kyoto University (to present)
December 2017 Audit & Supervisory Board Member of CMIC HOLDINGS Co., Ltd. (to present)

Status of Important Concurrent Posts
-Professor, Graduate School of Advanced Integrated Studies in Human Survivability, Kyoto University
-Director, The Outlook Foundation
-Director, The Grew Bancroft Foundation
-Outside Director, Nikko Asset Management Co., Ltd.
December 2017 External Audit and Supervisory Board Member of CMIC HOLDINGS Co., Ltd. (to present)

Dr. Mayer is the External Corporate Director of CMIC HOLDINGS Co., Ltd.. Dr. Mayer received his BA and Ph.D. from the University of California, Berkeley. After serving as President at Berkeley Antibody Company, and Vivigen, Inc., he studied Japanese at Keio University in Tokyo and was also a research student at Keio University’s Business School and the National Children’s Hospital. Upon returning to the US, he worked in the San Francisco office of McKinsey & Company before establishing his own management consulting practice in the San Francisco Bay Area in 1995. He has spent the last 25 years focusing on healthcare business strategy in the US and Japan and has helped numerous US and European companies with their Japan development strategies, as well as Japanese companies with their work in the US. In addition to biopharmaceutical development, Dr. Mayer also works in the areas of population health management and healthcare IT.

April 1972 Joined Mitsui Pharmaceuticals, Inc.
January 2001 Joined Nihon Schering K.K. (currently Bayer Yakuhin, Ltd.)
August 2005 Joined the Company, General Manager in charge of the Business Promotions Department (Tokyo)
July 2011 General Manager, Quality Management Promotion Office, Clinical Development Div. I, the Company
October 2012 General Manager, Resource Management Office, CMIC Co., Ltd.
October 2015 Business Planning Division, Site Support Institute Co., Ltd.
August 2018 Business Development Division, Site Support Institute Co., Ltd.(to present)
December 2018 Audit and Supervisory Board Member of CMIC HOLDINGS Co., Ltd. (to present)

April 1983 Joined Sankyo Co., Ltd. (currently Daiichi Sankyo Co., Ltd.)
September 2019 Joined CMIC Co., Ltd., General Manager in charge of QMS Department, QM Div.
January 2022 Director, and Head of Real & Virtual Lab, CMIC HealthCare Institute Co., Ltd.
December 2022 Audit and Supervisory Board Member of CMIC HOLDINGS Co., Ltd. (to present)

Kei Hata
External Audit and Supervisory Board Member

April 1984 Admitted to the TOKYO BAR Association -Joined Kazama & Co. Law Offices (currently Hata & Co. Law Offices)
December 2015 External Audit and Supervisory Board Member of CMIC HOLDINGS Co., Ltd. (to present)

November 1977 Joined Showa Audit Corporation (currently Ernst & Young ShinNihon LLC)
August 1981 Registered as Certified Public Accountant
August 2008 Executive Director, Ernst & Young ShinNihon LLC
August 2012 Senior Managing Director, Ernst & Young ShinNihon LLC
July 2014 Executive Vice President, Ernst & Young ShinNihon LLC
July 2016 Established Hidetoshi Watanabe Certified Public Accountant Office (to present)
June 2017 Outside Director, Audit and Supervisory Committee Member, Business Brain Showa-Ota Inc.(to present)
Status of Important Concurrent Posts
-Outside Director, Audit and Supervisory Committee Member, Business Brain Showa-Ota Inc.
December 2018 External Audit and Supervisory Board Member of CMIC HOLDINGS Co., Ltd. (to present)

October 1991 Joined Aoyama Audit Corporation(currently PricewaterhouseCoopers Aarata LLC)
March 1997 Joined PwC Consulting Co., Ltd. (currently IBM Japan Ltd)
October 1999 Joined ChuoAoyama Audit Corporation
March 2001 Joined Sanwa Capital Finance Ltd. (currently Mitsubishi UFJ Capital Co., Ltd.)
December 2002 Joined Phoenix Capital Co., Ltd.
March 2003 Director, Phoenix Capital Co., Ltd.
April 2006 Representative Director, Ascent Partners (to present)
June 2015 Outside Corporate Auditor, MORITA HOLDINGS CORPORATION (to present)
June 2017 Outside Audit & Supervisory Board Member, Wealth Management, Inc. (to present)

Significant concurrent positions outside the Company:
Representative Director, Ascent Partners
Representative Corporate Auditor, MORITA HOLDINGS CORPORATION
Outside Audit & Supervisory Board Member, Wealth Management, Inc.

March 2000 Resigned from TONETS CORPORATION
April 2000 Joined CMIC HOLDINGS Co., Ltd.
March 2001 Board Director
October 2002 Managing Director and CFO of CMIC HOLDINGS Co., Ltd. Division head of Administration Division and Director of Finance and Accounting Department
October 2003 Vice President, Director, and CFO of CMIC HOLDINGS Co., Ltd.
October 2004 Vice President, Representative Director and CFO of CMIC HOLDINGS Co., Ltd.
December 2007 Resigned from Board Director of CMIC HOLDINGS Co., Ltd.
December 2009 Board Director of CMIC HOLDINGS Co., Ltd.
December 2010 Resigned from Board Director of CMIC HOLDINGS Co., Ltd.
December 2015 Audit and Supervisory Board Member of CMIC HOLDINGS Co., Ltd. (to present)

Dr. Suzuki has been the Chief Scientific Officer of CMIC HOLDINGS since October 2014. He is responsible for evaluating new businesses, especially in next-generation antibodies, medium- and large-molecule drugs, and diagnostics and biomarkers, from the scientific point of view. Prior to joining CMIC, Dr. Suzuki served in several roles at Takeda Pharmaceuticals beginning in 1980. As Director of Frontier Research Laboratories, he led several projects for the development of regenerative medicines, nucleic acid medicines and peptide medicines. As the pharmacology group leader, Dr. Suzuki also led projects for the development for GnRH antagoists, insulin secretagogues, and small-molecule G-protein coupled receptor of anti-obesity drugs. His involvement in the development of Sandwich-ELISA, the measurement system of Amyloid β40/42, contributed to the pathology understanding of Alzheimer’s disease. Dr. Suzuki said that he would contribute to the innovative drug development for new modalities like next-generation antibodies, cyclic peptide and nucleic acid. Dr. Suzuki earned a master’s degree in Chemistry from Kyoto University and a doctoral degree from Gifu Pharmaceutical University. He was a visiting research fellow at Case Western Reserve University in Ohio in 1993.

November 1989 Passed the national bar examination
April 1992 Registered as attorney at law, Daini Tokyo Bar Association Joined Hamada &
Matsumoto (currently Mori Hamada & Matsumoto)
April 2005 Partner, Mori Hamada & Matsumoto 
June 2019 Outside Corporate Auditor, KITO CORPORATION 
June 2022 Outside Director, Audit and Supervisory Committee Member, SPARX Group
Co., Ltd. (to present)
December 2022 External Audit and Supervisory Board Member of CMIC HOLDINGS Co.,
Ltd. (to present)
January 2023 Senior Counsel, Mori Hamada & Matsumoto
July 2023 Outside Director, The Prudential Life Insurance Company, Ltd. (to present)
January 2024 Special Counsel, Gaien Partners (to present)
June 2024 Outside Audit & Supervisory Board Member, Daifuku Co., Ltd. (to present)